The anti‐obesity effect of the BRS‐3 agonist was still reportedly observed in Npy−/−, Mc4r−/−, Cb1r−/−, and Lepr−/− mice (Guan et al., 2010). The gene discussed is LEPR; the disease is obesity due to melanocortin 4 receptor deficiency.